A recombination between the short homologous regions of nucleotide sequences in the retroviral vector and packaging cell line has been thought to be a major cause of the production of replication-competent retrovirus (RCR). Therefore, the removal of overlapping sequences between the vector and the packaging constructs is crucial for minimizing the possibility of homologous recombination, and therefore, the production of RCR. We have recently constructed a series of retroviral vectors that contain no viral coding sequences, but still produce high viral titer and high-level gene expression. However, many previously constructed murine leukemia viurs (MLV)-based packaging constructs contained significantly long 5 0 and/or 3 0 untranslated regions of MLV, which are also present in the retroviral vector, and as such could possibly lead to homologous recombination. To make a retroviral production system that is free from homologous recombination, we constructed expression plasmids for gag-pol and env, precisely starting from the start codon and ending at the stop codon of respective open reading frames. When the packaging function was provided from one plasmid, a vector containing bits of all three viral coding sequences produced RCR at a significant frequency, while our vector remained free of any RCR. Our retrovirus production system is anticipated to have the minimum possible frequency of RCR production due to the elimination of potential sites for homologous recombination. Based on these results, a highly efficient new packaging line Vamp that contains no overlapping sequences with our retroviral vector was also developed. Gene Therapy (2003) 10, 706-711. doi:10.1038/sj.gt.3301892
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Keywords: retroviral vector; packaging line; homologous recombination; RCR Murine leukemia virus (MLV)-based vectors are the most frequently used gene delivery system, employed in almost 40% of approved protocols and 50% of patients who have been subjected to or are undergoing clinical trials. However, there are many problems that need to be improved in order for MLV-based vectors to become a viable form of gene delivery vehicle in actual clinical settings. In particular, the issue of safety has often been raised because of the possibility of the production of replication-competent retrovirus (RCR). The mechanism of RCR generation still remains poorly understood, but it has been thought to result from homologous recombination between the same nucleotide sequences present in the vector and in the packaging constructs. Indeed, it has been reported that homologous recombination could occur between as very short regions of homology as 7 or 11 bp.
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We have recently constructed a series of retroviral vectors that are absent of any viral coding sequences without compromising viral titer or the level of gene expression. 4 These vectors are thought to be safer than other existing vectors harboring viral coding sequences because the probability of homologous recombination between the vector and the packaging genome is much lower with these newly developed vectors. However, almost all available packaging constructs contain not only viral coding sequences, gag-pol and env, but also transcribe viral non-coding sequences that are also present in the vector. Therefore, it was necessary to develop packaging constructs that do not contain any viral nucleotide sequences overlapping with those in the vector. In this study, we developed packaging constructs lacking any viral non-coding sequences and tested them for the production of RCR as well as their viral production efficiency. In a specially designed shotgun RCR test system, it was found that RCR could indeed be produced when there are overlapping nucleotide sequences between the vector and the packaging constructs. The frequency of RCR generation increased as the length of the overlapping sequences increased. When newly constructed packaging expression vectors lacking non-coding retroviral sequences were used together with our vector that is absent of viral coding sequences, no RCR was produced. On the contrary, well-known retroviral vector MFG 5 that contains all three viral coding sequences produced a significant number of RCR. Our results indicate that the use of vectors and packaging constructs, which do not have any overlapping sequences, is vital for the RCR-free retroviral production system.
We first tested whether the presence of overlapping sequences could indeed generate RCR. To maximize the frequency of homologous recombination, we used the packaging construct entitled pkat2ampac 6 in which gag-pol and env are expressed in the form of c -MLV genome, while the U3 region of 5 0 LTR and 3 0 LTR regions were replaced with the HCMV (human cytomegalovirus) IE (immediate-early) promoter and SV40 polyA, respectively (Figure 1a) . In addition to the viral coding sequences, pkat2ampac also contains 58-and 70 bp-long viral non-coding sequences upstream from the start codon of the gag gene and downstream from the stop codon of the env gene. Two retroviral vectors were used for comparison, MFG-Neo 7 and MIN 4 ( Figure 1a) . The former contains all three viral coding sequences, 420 bp for gag, 377 bp for pol and 99 bp for env, while the latter does not have any viral coding sequences. pkat2ampac was transfected to 293T cells together with one of two retroviral vectors. Two days later, cell-free viral supernatants were prepared using the 0.45 mm filter, and taken to infect Mus dunny cells. Infected cells were split every 3-4 days. After three passages, cell-free culture supernatants were used to infect BAG 8 cells. BAG cells contain the integrated retrovirus expressing bgalactosidase and Neo that can be rescued by any packaging function including gag, pol, and env. Three days after infection, cell-free culture supernatants were used to infect NIH3T3 cells, followed by G418 selection. As shown in Figure 1b , in four independent experiments using varying concentrations of plasmids, MFG-Neo produced a large number of G418-resistant colonies. On the contrary, MIN produced a minimum 1000-fold less of G418-resistant colonies than did MFG-Neo under identical conditions. Although MIN does not have any viral coding sequences, it still produced a small number of RCR, presumably because it contains overlapping nucleotide sequences with pkat2ampac in its 5 0 and 3 0 untranslated region ( Figure 1a ). These results suggested that the possibility of generating RCR can be decreased by reducing sequences overlapped.
The above results suggested that it would be important to remove all possible overlapping nucleotide sequences between the vector and packaging constructs in order to minimize the production of RCR. Many gagpol-or env-expressing vectors previously used to construct the packaging lines contain viral non-coding sequences that are also present in the retroviral vector. For instance, some env expression vectors contain nucleotide sequences that are present between the stop codon of env and the 5 0 end of the 3 0 LTR. 6,9-11 Similarly, some gag-pol expression vectors contain a part of the 5 0 untranslated region upstream from the start codon of gag.
9,10,12,13 These sequences are also present in all available retroviral vectors, and thus can be used as a template for homologous recombination.
We constructed two types of packaging constructs, using pCA as a backbone, for gag-pol, and env, containing only the coding region of each open reading frame ( Figure 2a ). pCA is a mammalian expression vector containing not only the promoter but also the entire transcribed, untranslated region of the IE region of HCMV. 14 The first packaging construct, pVM-GPE, expresses gag-pol and env genes in one plasmid. However, unlike pkat2ampac, viral coding sequences begin precisely at the start codon of the gag gene and end precisely at the stop codon of the env gene. Two other packaging constructs were designed to express the gagpol gene (pVM-GP) and the amphotropic env gene (pVM-AE) from two separate plasmids. Retroviral vector MIN does not have any overlapping sequences with pVM-GP and pVM-AE, while in MFG, 420 and 99 nucleotide sequences are still overlapped in these packaging constructs.
We carried out the RCR assay, first using our newly constructed packaging construct pVM-GPE. In three independent experiments, no colonies were found from our vector MIN, while MFG still produced a significant number of colonies (Figure 2b) . However, the frequency of RCR generation with MFG was decreased by almost 1000-fold than when pkat2ampac was used. These results demonstrated that no RCR was produced when newly constructed packaging constructs lacking any viral non-coding sequences were used together with our vector free of viral coding sequences. These data also confirmed the above result showing that the frequency of RCR generation was dependent on the extent of the and passaged every 3-4 days at a 1:10 subcultivation ratio. After three passages, cell-free culture supernatants from Mus dunny cells were used to infect BAG (12) cells. The medium was replaced after 24 h using standard culture medium (DMEM supplemented with 10% fetal bovine serum, 120 mg of penicillin G per ml, and 200 mg of streptomycin sulfate per ml).
Two days later, cell-free culture supernatants were used to infect NIH3T3 cells followed by a G418 selection.
Retroviral vector production system Seung Shin Yu et al overlapping sequences between the vector and the packaging construct. Next, we tested the possibility of RCR generation using 'split-function' packaging plasmids, pVM-GP and pVM-AE (Figure 2a) . With a packaging function in two different plasmids, no G418-resistant colony was found from the MFG as well as the MIN vector in three independent experiments (Figure 2b ). There was no possibility for homologous recombination when MIN was used, while at least three recombination events would be needed to form an RCR in the case of MFG. Our data showed that no RCR was produced even in the case of MFG when viral genes are expressed in two separate constructs, indicating that even one more recombination event could significantly decrease the possibility of RCR generation.
Theoretically, at least two recombination events would be needed to form an RCR with a combination of MFG and pVM-GPE (Figure 2a) . In order to determine the genomic structure of the RCR, total cellular RNA was extracted from RCR-infected NIH3T3 cells followed by Northern hybridization analysis. When the 4070A env gene fragment was used as a probe, two RNA bands of approximately 8 and 3 kb appeared that were not present from uninfected NIH3T3 or BAG lines (Figure 3b) . The 8 kb RNA band corresponds to the size of the full-length retroviral genome, while the 3 kb fragment represents the subgenomic fragment, suggesting the presence of a viral structure similar to a full-length RCR.
To identify the site of recombination, a segment covering the env gene and the 3 0 LTR in the RCR genome was amplified by PCR using genomic DNA from RCRinfected NIH3T3 cells using the forward primer env25 and the reverse primer LTR23 (Figure 3a) . DNA fragment of the predicted size (375 bp) was obtained from four independent clones of RCR-infected NIH3T3 cells but not from the parental NIH3T3 cells or BAG cells (Figure 3c ). These results indicated that homologous recombination occurred between the 3 0 end of the env gene of the packaging plasmid and the 3 0 end of the MFG vector.
The amplified fragment was cloned and sequenced. DNA sequences from one representative clone confirmed that the RCR was a recombinant composed of the env sequence of VM-GPE joined to a c-terminal portion of env and the LTR of MFG (Figure 3d ). Based on the nucleotide sequence analysis, the recombination seemed to have occurred in the region between nucleotides 1897 and 1947 of env.
To develop the amphotropic packaging cell line using our new packaging plasmids described above, a hygromycin resistance marker was introduced into pVM-GP to generate the pVM-GPh. 293T cells were transfected with 10 mg of pVM-GPh and 2 mg of pVM-AE followed by drug selection. Thirty-five hygromycin B resistant subclones were selected and assayed for the expression of the env gene by real-time RT-PCR. The five clones displaying the highest env gene expression were further evaluated for the production of actual viral particles by transiently transfecting these subcloned cells with MINLacZ 4 and then comparing viral titer produced. The clone with the highest titer, designated 'Vamp', was passaged twice a week for 6 weeks without selection, and transiently transfected with MIN-LacZ for virus production. During the 6 weeks of continuous culture of Vamp without selection, we were able to produce transient viral supernatants with relatively constant titers (Table 1) . These transient supernatants were routinely screened for RCR as described and all were found to be consistently negative.
Next, we also tested whether a producer line derived from the Vamp packaging clone was stable and free of RCR. 293T cells were transfected with pVM-GP, VSV-G expressing pRV67 15 plasmid, and MIN vector. Fortyeight hours later, cell-free culture supernatants were taken and used to transduce Vamp cells. These transduced cells were passaged for 6 weeks without selection, and the culture supernatants from the third and 12th 14 The DNA fragment covering the full-length IE promoter of HCMV, its entire 5 0 untranslated region, and the BGH poly A region was cloned by PCR amplification of pCN, using primer pairs CMV5 (5 0 ACGCGTTGACATTGATTATTG3 0 ) and pA3 (5 0 GTCTACTCCCCAGCATGCCTG3 0 ). The amplified fragment was cloned into the NdeI/SalI sites of pUC19, resulting in pCA. The gag-pol region of MLV (Genbank #J02255, nucleotides 621 -5837) was amplified with gp5 (5 0 GCTAGCGAATTCCATGGGCCAGACTGTTACC) and gp3 (5 0 ATCCCAGTCTGGGCGCT3 0 ) primers, and cloned into the EcoRI/NotI site of pCA, generating pVM-GP. To construct pVM-GPE, the 3 0 end of pol and the entire env gene of amphotropic 4070A MLV was amplified by PCR with primers pol5 (5 0 TCTAGAGACTGGGTGCTCC3 0 ) and envN3 (5 0 GCGGCCGCTCATGGCTCGTACTCTATGG3 0 ) and cloned into the XbaI/NotI site of pVM-GP. To construct pVM-AE, the 4070A env gene (Genbank #M33469, nucleotides 37-2001) was amplified using pHIT456 11 as a template with env5 (5'GAATTCGGCTTGTCGACATGGCGCGTT-CAACGCTCTC3'), and env3 (5'GAATTCTCATGGCTCGTACTC-TATGG3') primers, and cloned into the EcoRI site of pCA. Sequences derived from MLV and 4070A are indicated by light and dark gray bars, respectively. The crossing lines indicate the sites where homologous recombination can occur resulting in the generation of RCR. (b) RCR production by cotransfection of pVM-GPE and MFG-neo. The experimental conditions were same as described in Figure 1 , except the new packaging constructs were used instead of pkat2ampac. The titer of the virus used to infect Mus dunny cells ranged from 1.0X10 6 to 4X10 6 /ml. Retroviral vector production system Seung Shin Yu et al passages were evaluated for viral titer and RCR production. As shown in Table 2 , the viral titer was stably maintained for 6 weeks, and RCR was not detected. Similar results were obtained with a cell line containing the MFG-neo vector.
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The potential for the generation of RCR in producer lines has been a primary safety concern in the field of retroviral gene therapy particularly because there is only limited knowledge of the risks involved in MLV exposure in humans. Although amphotropic MLV was not identified as an acute pathogen in rhesus monkeys, 16 the occurrence of lymphomas associated with a recombinant, predominantly amphotropic MLV in immunosuppressed macaques, 17 heightened concerns about the risk of MLV exposure in humans. 16, 17 Therefore, there has been much effort to improve the design and construction of packaging lines to help minimize such risks. The third-generation packaging lines are the socalled 'split-function' packaging lines where gag-pol and env genes are introduced as separate transcription units, so that at least three recombination events would be needed to form an RCR. However, it was reported that RCR was produced even from the third-generation packaging lines, suggesting that there was still much room for improvement in designing both packaging lines and vectors. 1, 3 In this study, we demonstrated that RCR could indeed be generated when there are overlapping nucleotide sequences between the vector and the packaging constructs. The longer the overlapping sequences were, the higher the frequency of RCR that was produced.
Although MFG did not produce RCR with our 'splitfunction' packaging constructs, it is still important to note that the possibility of generating RCR still exists as long as the sequence homology between the vector and packaging constructs, however small it may be, is present. This becomes particularly important when one tries to scale-up the vector production or increase the proviral copy number to generate a high-titer producer line. Although recombination would occur at a very low frequency, the production of retroviral vectors on a scale necessary for clinical trials increases the chance of detecting a rare recombinant. It has indeed been reported that the possibility of RCR generation is increased when the amount of vector produced increases. 18 In addition, a high proviral copy numbers in a producer cell would certainly enhance the probability of generating RCR by increasing the number of viral sequences available for homologous recombination. Sheridan et al 18 tried to overcome these problems using a different approach, but still fell short of developing the optimal production system. For example, their gag/pol expression plasmids lack 5 0 and 3 0 untranslated regions, but have a small deletion at the 3 0 end of the pol-coding sequence, resulting in a two-to five-fold lower viral titer due presumably to the impaired function of the truncated integrase. Furthermore, in one of their gag/pol expression vectors, a series of degenerate codons were introduced to the gag-coding sequence in an effort to avoid an overlap with the so-called extended packaging signal sequence present in the vector. However, this region has been shown to play little role in viral packaging, 4, 19 and there is no reason to go through this complex mutational analysis creating yet another complexity to the retroviral production system.
Our results strongly indicated that homologous recombination could indeed occur and that our retroviral production system, which has no overlapping sequences between the vector and the packaging constructs, should be capable of producing high-titer, RCR-free retroviral vector for clinical use. Vamp cells were passaged twice a week for 6 weeks without selection, and transiently transfected with MIN-LacZ for virus production.These transient supernatants were screened for RCR production, and all were negative. 293T cells were transfected with pVM-GP and the VSV-G envelope expression plasmid pRV67 together with each retroviral vector, MIN or MFG-neo. Two days later, Vamp cells were transduced with each VSV-G pseudotyped retroviral vector. Transduced cells were passaged for 6 weeks without selection. The viral titer and RCR production were evaluated using supernatnats from the third and 12th passaged populations.
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